Bioabsorbable Versus Durable Polymer Drug Eluting Stent (DES): a Meta-analysis
Bioabsorbable Versus Permanent Polymer Bare Metal Stents in Saphenous Vein Graft Disease: Insights From a Meta-analysis of 6221 Patients
1 other identifier
observational
6,221
1 country
1
Brief Summary
Evidence supporting use of bioabsorbable polymer drug eluting stents (BP-DES) is uncertain. Thus the investigators planned a meta-analysis to compare outcomes of BP-DES versus PP-DES in obstructive coronary artery disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2011
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2011
CompletedFirst Submitted
Initial submission to the registry
October 24, 2011
CompletedFirst Posted
Study publicly available on registry
November 8, 2011
CompletedNovember 8, 2011
November 1, 2011
1 month
October 24, 2011
November 4, 2011
Conditions
Outcome Measures
Primary Outcomes (5)
late coronary lumen loss
9 month
target lesion revascularization
9 month
overall mortality
1 year
Late stent thrombosis
1 year
Myocardial Infarction
1 year
Secondary Outcomes (1)
Binary restenosis
9 months
Study Arms (2)
permanent polymer DES
bioabsorbable polymer DES
Interventions
patients with coronary artery disease treated by percutaneous coronary intervention with BP-DES are compared with patients with coronary artery disease treated by percutaneous coronary intervention with PP-DES
Eligibility Criteria
Patients with coronary artery disease with indication to percutaneous coronary intervention
You may qualify if:
- randomized studies
- studies reporting clinical outcomes as overall death and/or acute myocardial infarction and/or late stent thrombosis (ARC definition)\[\*\*\] and/or target lesion revascularization and/or late lumen loss
- follow up period longer than 6 months.
You may not qualify if:
- duplicate reporting (in which case the manuscript reporting the largest sample or the longest follow-up was selected)
- inability to compute risk estimates due to absence of clinical event in one of the groups
- studies presenting composite major adverse cardiac event (MACE) and not individual end points.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ospedale Maggiore della Carità
Novara, 28100, Italy
Related Publications (1)
Lupi A, Rognoni A, Secco GG, Lazzero M, Nardi F, Fattori R, Bongo AS, Agostoni P, Sheiban I. Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients. Eur J Prev Cardiol. 2014 Apr;21(4):411-24. doi: 10.1177/2047487312467745. Epub 2012 Nov 14.
PMID: 23152364DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alessandro Lupi, MD
AOU Maggiore della Carita
Study Design
- Study Type
- observational
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
October 24, 2011
First Posted
November 8, 2011
Study Start
August 1, 2011
Primary Completion
September 1, 2011
Study Completion
October 1, 2011
Last Updated
November 8, 2011
Record last verified: 2011-11